Innate Pharma SA

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024.

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia and h.

Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma (IPHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that first preclinical data for its asset IPH45, a novel and differentiated exatecan-Antibody Drug Conjugate (ADC) targeting Nectin-4, were presented in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024. In preclinical studies, data demonstrated that IPH45 effectively inhibits Nectin-4 expressing tumor.

Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma files its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F.

Innate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F

Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma reports Full Year 2023 financial results and business update.

Innate Pharma Reports Full Year 2023 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below. Participants will be Sonia Quaratino, Executive Vice President, Chief Medical Officer, Yannis Morel, Executive Vice President, Chief Operating Officer and Arvind Sood, Executive Vice President, President of US Operations. 2nd Annual.

Innate Pharma Announces Its Participation to Upcoming Investor Conference

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2023. Participants during the call will be: Hervé Brailly, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel,.

Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to present Nectin-4 Antibody Drug Conjugate IPH45 preclinical data at AACR 2024.

Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

MARSEILLE, France--(BUSINESS WIRE)--First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma.

Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma

Innate Pharma is a European biotech specializing in the development of immunotherapeutics for various cancer types. Their most advanced projects focus on engaging and activating natural killer cells, with promising results in clinical trials. The company has strong financial backing and multiple partnerships, making it an attractive investment opportunity.

Innate Pharma: Worth A Deeper Look

Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.

Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the lacutamab IND. On October 5, Innate announced that the lacutamab IND has been placed on partial clinical hold by FDA following a recent patient death in the TELLOMAK study. The death of a patient affected by Sézary syndrome was initially considered.

Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has strengthened the Company's leadership and corporate governance with the appointment of two new Executive Board members. Arvind Sood, Executive Vice President (EVP), President of US Operations, Dr Sonia Quaratino, EVP, Chief Medical Officer are thus joining Hervé Brailly, interim Chief Executive Officer and Yannis Morel, EVP, Chief Oper.

Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

Sanofi

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate's ANKET® (Antibody-based NK Cell Engager Therapeutics) platform pursuant to the terms of the research collaboration and license agreement signed in December 2022. Following a research collaboration period, Sanofi will be responsible.

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Mondher Mahjoubi has resigned from his position as Chief Executive Officer (CEO) and Chairman of the Executive Board of the Company, effective as of January 2024, to pursue a senior level opportunity at a large pharmaceutical company. Hervé Brailly, Innate Pharma's current Chairman of the Supervisory Board, former CEO and co-founder is appointed as interim CE.

Innate Pharma Announces Leadership Change

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that the updated efficacy and safety results from an open-label, first-in-human, Phase 1/2 dose-escalation study of SAR443579 / IPH6101, an investigational CD123 targeting NKp46/CD16-based Natural Killer Cell Engager (NKCE) from a joint research collaboration between Innate Pharma and Sanofi were shared in a poster presentation at the American Society of Hematolog.

Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced positive final results from the Phase 2 TELLOMAK study in Sézary Syndrome (SS). The results were presented at the ASH 2023 Annual Meeting, in San Diego, California. As of May 1, 2023, data cutoff, patients in the Sézary Syndrome cohort (cohort 1, n=56) received a median of 5 prior systemic therapies, including mogamulizumab, and had a median follow-up of 14.4 mont.

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual KOL (Key Opinion Leader) event on lacutamab, a first-in-class anti-KIR3DL2 antibody currently in development for cutaneous T-cell lymphoma (CTCL) and peripheral T cell lymphoma (PTCL), on Tuesday, December 12, 2023, at 7:00AM PST (4:00PM CET). The event will feature Prof. Pierluigi Porcu, M.D., Director, Division of Hematologic Malignan.

Innate Pharma to Host Virtual KOL Event on Lacutamab

Innate Pharma S.A. (NASDAQ:IPHA ) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Henry Wheeler - VP, IR and Communication Mondher Mahjoubi - CEO Sonia Quaratino - Chief Medical Officer Yannis Morel - EVP, BD and Product Portfolio Strategy Conference Call Participants Rabib Chaudhury - Leerink Partners Carly Kenselaar - Citi Arthur He - H.C.

Innate Pharma S.A. (IPHA) Q3 2023 Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its revenues and cash position for the first nine months of 2023. “With our strong cash position, we continue to execute against our strategy to develop innovative proprietary and partnered assets with key players. We look forward to this year's ASH Annual Meeting where we will present the final results of the lacutamab TELLOMAK Phase 2 study in patients with Séza.

Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2023. Participants during the call will be: Mondher Mahjoubi, Chief Executive Officer Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development Sonia Quaratino,.

Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces new clinical data for lacutamab and SAR443579/IPH6101 at ASH 2023.

Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. Jefferies London Healthcare Conference Event Date: November 15, 2023, London, UK 6th Annual Evercore ISI HealthCONx Conference Event Date: November 28, 2023, Miami, USA Investir Day Event Date: November 28, 2023, Paris, France About Innate Phar.

News for Innate Pharma SA Stock (IPHA)